Antibodies, Effective in Preventing Symptomatic COVID-19 Infections?

While the world focuses on the rollout of COVID-19 vaccines, antibody treatments that can be given to patients after they've contracted the disease haven't been in the spotlight.

Regeneron's cocktail of two monoclonal antibodies synthesized to block the SARS-CoV-2 virus got plenty of press when it was given to President Trump, who subsequently recovered from COVID-19. In November 2020, Regeneron won emergency use authorization from the Food and Drug Administration for the cocktail, called REGN-COV2, in treating patients with mild to moderate cases of the disease. It also scored a contract with the U.S. government to supply 300,000 doses. That deal was just the beginning.

Check it right here.